Vivek Subbiah: How Daraxonrasib Expands Treatment Access for Pancreatic Cancer
Vivek Subbiah/LinkedIn

Vivek Subbiah: How Daraxonrasib Expands Treatment Access for Pancreatic Cancer

Vivek Subbiah, Director of Early Phase Drug Development Program at NYU Langone Health, shared on X:

“Following World Pancreatic Cancer Day, I’m pleased to share our comment with Razelle Kurzrock, MD in Nature Reviews Clinical Oncology

‘An imprecise label in the era of precision medicine.’

  • The FDA approved daraxonrasib, the first pan-RAS inhibitor, for metastatic pancreatic adenocarcinoma in two groups of patients: those who have had at least one prior systemic therapy, and those who are not candidates for multiagent systemic therapy.
  • Critics say the second clause isn’t evidence based. They have a point about the trial data. But trials mostly enroll patients with good performance status, and that isn’t what metastatic pancreatic cancer looks like in clinic. Most of our patients never get to second-line therapy because their condition declines first.
  • So the imprecision in the label is what gives those patients access. A tighter label would have shut out the people who need the drug most, and they would have had to wait for evidence that may never come from a conventional trial. Real-world evidence should settle the remaining uncertainty. Until then, I think this is a case where an imprecise label serves precision medicine well.”

Title: An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval

Authors: Vivek Subbiah, Razelle Kurzrock.

Read the Full Article

You may also be interested in:

Vivek Subbiah: How Daraxonrasib Expands Treatment Access for Pancreatic Cancer